Abstract
The patient was a 70-year-old woman with a gastrointestinalstromaltumor (GIST)of the small intestine and synchronous colonic cancer, who underwent laparoscopic right colectomy and resection of the small intestine. We started imatinib therapy because GIST belongs to a high-risk group, according to the modified Fletcher classification. Gastric cancer was diagnosed 2 years after the start of imatinib therapy. Only 4 of the 12 GIST cases seen at our institution over the last 5 years were complicated by another cancer. This is the first case of GIST in which 2 other cancers occurred at both the same and different times. We suggest that imatinib might be a factor in the development of gastric cancer.
MeSH terms
-
Adenocarcinoma* / drug therapy
-
Adenocarcinoma* / surgery
-
Aged
-
Antineoplastic Agents / therapeutic use
-
Appendiceal Neoplasms / drug therapy
-
Appendiceal Neoplasms / pathology*
-
Appendiceal Neoplasms / surgery
-
Female
-
Gastrointestinal Stromal Tumors* / drug therapy
-
Gastrointestinal Stromal Tumors* / surgery
-
Humans
-
Ileal Neoplasms / drug therapy
-
Ileal Neoplasms / pathology*
-
Ileal Neoplasms / surgery
-
Imatinib Mesylate / therapeutic use
-
Neoplasms, Multiple Primary / drug therapy
-
Neoplasms, Multiple Primary / pathology*
-
Neoplasms, Multiple Primary / surgery
-
Stomach Neoplasms / drug therapy
-
Stomach Neoplasms / pathology*
-
Stomach Neoplasms / surgery
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Imatinib Mesylate